<DOC>
	<DOCNO>NCT00386841</DOCNO>
	<brief_summary>The purpose study determine whether outcome follow antidepressant treatment use tool evaluate endo-phenotypes depression .</brief_summary>
	<brief_title>Outcome Following Antidepressant Treatment Possible Endo-Phenotypes Major Depression</brief_title>
	<detailed_description>The research depression year focus identification endo-phenotypes . Endo-phenotypes heritable biological psychological marker , commonly find patient healthy relative general population . Recent study point disturbed regulation hypothalamic-pituitary-adrenocortical ( HPA ) system possible endo-phenotype depression . The hypothesis AGENDA endo-phenotypes affect treatment antidepressant healthy first degree relative . AGENDA four week randomize , placebo-controlled , double-blind trial first degree relative patient diagnosis depression randomise two group , treat either placebo antidepressant medicine ( Cipralex ) . We expect include 80 healthy subject , predisposition depression , since one parent siblings recently treat depression . The subject examine four week treatment thorough interview concern psychiatric symptom ( SCAN ) , include depressive symptom , personality , perceive stress cognitive function . The effect antidepressant stress measure saliva-cortisol response combine dexamethasone corticotropin-releasing ( CRH ) hormone test . Additionally , MR PET scan 5-HT4 receptor function conduct 4 week treatment .</detailed_description>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Citalopram</mesh_term>
	<mesh_term>Dexetimide</mesh_term>
	<criteria>Offsprings sibling patient major depression Born Denmark European parent grandparent For woman ; pregnant breastfeeding Written inform consent Somatically illness handicap make participation study impossible Daily intake drug interfere corticosteroid escitalopram Hypersensitivity escitalopram , dexamethasone human corticotropinreleasing hormone Former medical psychological treatment disease affective schizophrenic spectrum Ongoing addiction alcohol psychoactive drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2009</verification_date>
	<keyword>Major depression</keyword>
	<keyword>First degree relative</keyword>
	<keyword>Escitalopram</keyword>
	<keyword>Cortisol</keyword>
	<keyword>Cognition</keyword>
	<keyword>Personality</keyword>
	<keyword>Endo-phenotype</keyword>
</DOC>